| MYELODYSPLASTIC SYNDROME
Reblozyl vs Rytelo
Side-by-side clinical, coverage, and cost comparison for myelodysplastic syndrome.Deep comparison between: Reblozyl vs Rytelo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRytelo has a higher rate of injection site reactions vs Reblozyl based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rytelo but not Reblozyl, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Reblozyl
Rytelo
At A Glance
SC injection
Every 3 weeks
Erythroid maturation agent
IV infusion
Every 4 weeks
Telomerase inhibitor
Indications
- beta Thalassemia
- MYELODYSPLASTIC SYNDROME
- Refractory anemia with ringed sideroblasts
- Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis
- MYELODYSPLASTIC SYNDROME
Dosing
beta Thalassemia 1 mg/kg SC every 3 weeks; increase to max 1.25 mg/kg if no reduction in RBC transfusion burden after at least 2 consecutive doses at 1 mg/kg.
MYELODYSPLASTIC SYNDROME (ESA-naive) 1 mg/kg SC every 3 weeks; increase up to max 1.75 mg/kg to maintain hemoglobin 10 g/dL to 12 g/dL.
Refractory anemia with ringed sideroblasts, Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (ESA-refractory or intolerant) 1 mg/kg SC every 3 weeks; increase to max 1.75 mg/kg if patient is not RBC transfusion-free.
MYELODYSPLASTIC SYNDROME 7.1 mg/kg administered as an intravenous infusion over 2 hours every 4 weeks; discontinue if no decrease in RBC transfusion burden after 24 weeks (6 doses) or if unacceptable toxicity occurs.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) headache, bone pain, arthralgia, fatigue, cough, abdominal pain, diarrhea, dizziness, hypertension, nausea, edema peripheral, dyspnea, musculoskeletal pain
Serious thrombosis/thromboembolism, hypertension, extramedullary hematopoietic masses, cerebrovascular accident, deep vein thrombosis
Most common (>=10%) Decreased platelets, decreased white blood cells, decreased neutrophils, increased AST, increased alkaline phosphatase, increased ALT, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, headache
Serious Sepsis, fracture, cardiac failure, hemorrhage
Pharmacology
Luspatercept-aamt is a recombinant fusion protein that binds several endogenous TGF-beta superfamily ligands, thereby diminishing Smad2/3 signaling and promoting erythroid maturation by increasing late-stage erythroid precursors (normoblasts) to reduce ineffective erythropoiesis in beta-thalassemia and MDS.
Imetelstat is an oligonucleotide human telomerase inhibitor that binds to the RNA template region of human telomerase (hTR), inhibiting telomerase enzymatic activity and reducing malignant stem and progenitor cell proliferation while inducing apoptotic cell death in MDS.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Reblozyl
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Rytelo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Reblozyl
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rytelo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Reblozyl
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Rytelo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Myelodysplastic Syndromes - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Myelodysplastic Syndromes - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ReblozylView full Reblozyl profile
RyteloView full Rytelo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.